Background pattern of a brain with neural connections

Team Parisiadou

Age-related RNA oxidation and ribosomal dysfunction in Parkinson’s disease vulnerable dopamine neurons

2026-Present

Parkinson’s disease (PD) involves the loss of certain dopamine-producing brain cells, but why some cells die while others survive remains unclear. We hypothesize that age-related damage to the protein synthesis machinery plays a central role in PD pathogenesis. Our team will utilize human brain samples and cells, refined genetic mouse models, and advanced tools to determine how, when, and where cell specific damage to the protein synthesis machinery disrupts proteostasis and promotes selective neuron loss in PD. By examining age-related effects and exploring potential mitigating approaches, we seek to uncover new strategies to delay or prevent PD progression.

Tags
Alpha-synucleinDisease modelsGBA (Glucocerebrosidase)LRRK2Organoid

Contributions

Stay tuned—this is where the team’s scientific contributions will be shared.

Accolades

Check back soon to see how this team is being recognized.

In the News

Decoding the Blueprint: Advancing Personalized Parkinson’s Treatments

Decoding the Blueprint: Advancing Personalized Parkinson’s Treatments

05/21/2026 — In our community, we often hear: “If you’ve met one person with Parkinson’s, you’ve met one person with Parkinson’s.” This isn’t just an adage — it’s a biological reality. This radical variability is exactly what makes the disease so difficult to outsmart. We’ve learned that a puzzle this fragmented cannot be solved with a single, broad stroke. Our goal isn’t to find one answer for everyone, but the right answer for the right person at the right time.

Aligning Science Across Parkinson’s and The Michael J. Fox Foundation Expand Global Research Initiative with $261M Investment Toward Personalized Treatments

Aligning Science Across Parkinson’s and The Michael J. Fox Foundation Expand Global Research Initiative with $261M Investment Toward Personalized Treatments

04/28/2026 — Today, Aligning Science Across Parkinson’s (ASAP), in partnership with The Michael J. Fox Foundation for Parkinson’s Research (MJFF), announced $261 million in new grant funding for the Collaborative Research Network (CRN) to map the biological blueprint of Parkinson’s disease and build a standardized toolkit of global research resources that are needed to turn discoveries into treatments.

Our Research Teams

Members of the CRN work diligently to advance our understanding of Parkinson’s disease. Learn more about recent CRN discoveries and achievements.